OD 36 hydrochloride is a potent inhibitor of RIPK2 kinase with an IC50 value of 5.3nM [1]. OD 36 hydrochloride mimics the interaction between the ATP adenine ring and the hinge region of RIPK2 KD, and utilizes the interaction between the cyclic linker group and the hydrophobic posterior pocket as well as the ribose binding region, thereby enhancing the affinity and selectivity for RIPK2[2]. OD 36 hydrochloride has been widely used in mouse peritonitis models to alleviate inflammation[3].
In vitro, OD 36 hydrochloride treatment (0.5μM) for 21 days significantly inhibited the osteogenic and chondrogenic differentiation induced by activin A in ATDC5 cells expressing mutant R206H ALK2 [4]. The 5.3nM OD 36 hydrochloride treatment for 24 hours significantly inhibited the invasion and metastasis of K7M2 cells promoted by macrophages[5].
In vivo, OD 36 hydrochloride treatment via intraperitoneal injection at a single dose of 6.25mg/kg can reduce the cell infiltration in a muramyl dipeptide (MDP)-induced peritonitis mouse model [6].
References:
[1] Shen S, Lu C, Ling T, et al. Current advances on RIPK2 and its inhibitors in pathological processes: a comprehensive review[J]. Frontiers in Molecular Neuroscience, 2025, 18: 1492807.
[2] Pham A T, Ghilardi A F, Sun L. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases[J]. Frontiers in pharmacology, 2023, 14: 1127722.
[3] You J, Wang Y, Chen H, et al. RIPK2: a promising target for cancer treatment[J]. Frontiers in pharmacology, 2023, 14: 1192970.
[4] Sánchez Duffhues G, Williams E, Benderitter P, et al. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva Derived Endothelial Cells[J]. Journal of Bone and Mineral Research Plus, 2019, 3(11): e10230.
[5] Maloney C, Kallis M P, Edelman M, et al. Gefitinib inhibits invasion and metastasis of osteosarcoma via inhibition of macrophage receptor interacting serine-threonine kinase 2[J]. Molecular cancer therapeutics, 2020, 19(6): 1340-1350.
[6] Tigno-Aranjuez J T, Benderitter P, Rombouts F, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease[J]. Journal of Biological Chemistry, 2014, 289(43): 29651-29664.
















